Condition: HPV 16+ Recurrent or Metastatic Cancer · HNSCC · Cervical Cancer · Sponsor: Therorna
This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors. The primary objectives of the study are to assess safety and tolerability of TI-0093 injection in patients with recurrent or metastatic solid tumors, and to determine the maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of TI-0093 injection.
This description comes directly from the study's public registry record.
Ye Guo · 0086-457-13501678472 · pattrickguo@gmail.com
The Drug Clinical Trial Institution of Shanghai East Hospital · 021-38804518-28329 · shdfgcp@163.com
Always discuss trial participation with your own doctor first.
| Shanghai East Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07081984